PLYX · Polaryx Therapeutics, Inc.
$2.00
+0.01 (+0.50%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed May 15, 2026
Market Cap
$94.21M
Shares
47.34M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alex Yang | CEO | $792,000 |
| Lisa Bollinger | Other | $482,500 |
| G. Michael Landis | CFO | $310,667 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alex Yang | CEO | $580,000 |
| G. Michael Landis | CFO | $87,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lisa Bollinger, MD | Chief Medical Officer | Resigned | 2026-07-21 |